RxDoctor Payments Data

Heather Funderburk, APRN

Family · Mount Ida, ARNPI 1033577234

Payments from drug & device makers

$374in general payments, 2019–2025

Across 23 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96
  • AstraZeneca$94
  • Pfizer$52
  • GSK$29
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$28
  • Lilly USA, LLC$28
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$374 in reported general payments places this provider in the 50th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$11,333
Medicare patients
174
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$117,459
MounjaroTirzepatide60$64,046
FarxigaDapagliflozin Propanediol49$53,724
TrulicityDulaglutide16$24,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$20,918
JanuviaSitagliptin Phosphate17$18,632
EliquisApixaban13$13,433
Tresiba Flextouch U-100Insulin Degludec13$11,341
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,334
LinzessLinaclotide17$11,155
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$8,205
Combivent RespimatIpratropium/Albuterol Sulfate16$7,847
Breo ElliptaFluticasone/Vilanterol13$7,828
Dexlansoprazole DrDexlansoprazole16$3,929
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$117,45996 claims
Lilly USA, LLCMounjaro, Trulicity$28$88,23676 claims
AstraZenecaFarxiga$94$53,72449 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$29$40,08070 claims
PfizerEliquis$52$13,43313 claims
AbbVieLinzess$96$11,15517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,103 family providers in Arkansas.

Other family in Mount Ida

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →